tiprankstipranks
Trending News
More News >
111 Inc (YI)
NASDAQ:YI

111 (YI) Price & Analysis

Compare
277 Followers

YI Stock Chart & Stats

$2.85
-$0.01(-2.07%)
At close: 4:00 PM EST
$2.85
-$0.01(-2.07%)

Bulls Say, Bears Say

Bulls Say
Asset-light Business ModelShifting to an asset-light model reduces fixed capital and operational overhead, improving operating leverage and liquidity. Structurally, using fulfillment partners preserves service capacity while lowering balance-sheet intensity, enabling faster scaling and less capital tied up in physical assets over months.
Return To Sustained ProfitabilityConsistent non-GAAP profitability and positive operating cash flow signal improving unit economics and execution on cost structure. Over 2-6 months this trend supports internal funding for operations, reduces refinancing needs, and indicates the business model can generate cash when paired with the asset-light strategy.
Positive Operating Cash Flow ConversionAbility to convert accounting results into operating cash provides resilience despite negative net income. This cash-generation capability supports working capital, funds strategic investments (e.g., AI platform plans) and reduces near-term reliance on external capital, strengthening operational sustainability.
Bears Say
Declining Revenue TrendA persistent revenue decline undermines scalability and margin recovery prospects. Structural top-line weakness reduces operating leverage, limits the impact of cost cuts, and makes sustaining recent profitability harder unless customer growth or GMV reverses, posing a multi-quarter headwind to durable growth.
Negative Shareholders' EquityNegative equity signals balance-sheet fragility and constrains financing options. Over months this heightens refinancing and covenant risk, can force dilutive capital raises or asset disposals, and limits strategic flexibility for investments or M&A, weakening long-term financial stability.
Sharp Free Cash Flow DeclineA severe drop in free cash flow reduces internal funding for growth and platform initiatives. Persistently depressed FCF increases dependency on external financing and impairs the company's ability to invest in supply chain, AI, or marketing—threatening sustained operational improvements.

111 News

YI FAQ

What was 111 Inc’s price range in the past 12 months?
111 Inc lowest stock price was $2.48 and its highest was $11.35 in the past 12 months.
    What is 111 Inc’s market cap?
    111 Inc’s market cap is $68.37M.
      When is 111 Inc’s upcoming earnings report date?
      111 Inc’s upcoming earnings report date is Mar 12, 2026 which is in 9 days.
        How were 111 Inc’s earnings last quarter?
        111 Inc released its earnings results on Dec 17, 2025. The company reported -$0.202 earnings per share for the quarter, missing the consensus estimate of N/A by -$0.202.
          Is 111 Inc overvalued?
          According to Wall Street analysts 111 Inc’s price is currently Overvalued. Get more investment ideas with TipRanks Premium
            Does 111 Inc pay dividends?
            111 Inc does not currently pay dividends.
            What is 111 Inc’s EPS estimate?
            111 Inc’s EPS estimate for its next earnings report is not yet available.
            How many shares outstanding does 111 Inc have?
            111 Inc has 5,067,436 shares outstanding.
              What happened to 111 Inc’s price movement after its last earnings report?
              111 Inc reported an EPS of -$0.202 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 2.924%.
                Which hedge fund is a major shareholder of 111 Inc?
                Currently, no hedge funds are holding shares in YI
                What is the TipRanks Smart Score and how is it calculated?
                Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

                  Company Description

                  111 Inc

                  111, Inc. operates an integrated online and offline platform in the healthcare market in the People's Republic of China. It operates through two segments, B2B and B2C. The company sells medical and wellness products through online retail, and wholesale and retail pharmacies, as well as provides value-added services that include online consultation services and electronic prescription services to consumers. It offers prescription and over-the counter drugs, including western and traditional Chinese medicines; nutritional supplements, such as vitamins and dietary products; contact lenses; medical supplies and devices comprising bandages and thermometers; and personal care products consisting of skin care, birth control, and sexual wellness products; and baby products. The company also operates an online marketplace where third-party sellers can directly sell to pharmacies; provides online loan application services to the clients of 1 Pharmacy, which include pharmacies and wholesalers; and data and supply chain integration services. As of December 31, 2021, it operated 14 offline retail pharmacies under the Yi Hao Pharmacy brand name in Guangzhou, Tianjin, Kunshan, Chongqing, and Wuhan provinces. In addition, the company offers warehousing, logistics, procurement, research and development, and consulting services; and software development and information technology support services. It serves pharmacies, pharmaceutical companies and distributors, medical professionals, and insurance companies. The company was formerly known as New Peak Group and changed its name to 111, Inc. in April 2018. 111, Inc. was founded in 2010 and is headquartered in Shanghai, the People's Republic of China.

                  111 (YI) Earnings & Revenues

                  Similar Stocks
                  Company
                  Price & Change
                  Follow
                  Rockwell Med
                  Dyadic International
                  Rein Therapeutics
                  Elutia
                  Neuphoria Therapeutics

                  Ownership Overview

                  0.05%0.36%99.60%
                  Insiders
                  0.36% Other Institutional Investors
                  99.60% Public Companies and
                  Individual Investors

                  Options Prices

                  Currently, No data available
                  ---
                  Popular Stocks